MetaCap

Akebia Therapeutics (AKBA) vs BGM Group (BGM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Akebia Therapeutics (AKBA) has outperformed BGM Group (BGM) over the past year, losing 75.1% versus a loss of 96.7%. Over five years, AKBA leads with a -85.6% price change compared with -98.3% for BGM. BGM Group is the larger company by market cap ($108.6 million vs $107.0 million), about 1.0 times the size.

Akebia Therapeutics converts more of its revenue into profit, with a net margin of -2.3% versus -52.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKBA-72.75%BGM-96.73%
+15%-44%-102%
Nov 21, 20251 yearNov 19, 2026
AKBA-86.13%BGM-98.38%
+50%-28%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKBA versus BGM key metrics
MetricAKBABGM
Share price$0.3855$8.13
Market cap$107.04M$108.57M
1-day change-8.71%0.00%
YTD return-76.06%-92.77%
1-year return-75.13%-96.73%
5-year return-85.56%-98.31%
EPS (TTM)$-0.17$-4.80
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$236.20M$37.92M
Revenue growth (YoY)+47.46%+51.09%
Net income (latest FY)$-5.34M$-19.94M
Gross margin83.29%16.64%
Operating margin9.95%-33.18%
Net margin-2.26%-52.59%
52-week high$1.73$263.70
52-week low$0.361$0.00
Distance from 52-week high-77.72%-96.92%
Analyst consensusstrong_buy—
Avg. price target upside+678.21%—
Average volume8.05M6.18K
Shares outstanding277.66M12.69M
Employees194—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AKBA has outperformed BGM by 21.6 percentage points over the past year.
  • Akebia Therapeutics is more profitable, keeping -2.3 cents of every revenue dollar as net income versus -52.6 cents for BGM Group.

About Akebia Therapeutics

AKBA stock →

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.

Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees

About BGM Group

BGM stock →

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.

Health Care · Biotechnology: Pharmaceutical Preparations

AKBA vs BGM FAQ

Which is bigger, Akebia Therapeutics or BGM Group?

BGM Group (BGM) is larger, with a market capitalization of $108.57M compared with $107.04M for Akebia Therapeutics (AKBA).

Which stock has performed better over the past year, AKBA or BGM?

AKBA returned -75.13% over the past 12 months, compared with -96.73% for BGM (price return, excluding dividends). Past performance does not predict future results.

Are Akebia Therapeutics and BGM Group in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons